Brentuximab Vedotin is a drug-conjugated antibody composed of an anti-CD30 monoclonal antibody; according to some recent phase II-III studies, it has reached an ORR of 70% in patients with MF/SS CD30+, and it is now commonly used starting from the second line of systemic therapy. The gene discussed is TNFRSF8; the disease is mycosis fungoides.